These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 14634544)

  • 1. Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study.
    Post MS; van der Mooren MJ; van Baal WM; Blankenstein MA; Merkus HM; Kroeks MV; Franke HR; Kenemans P; Stehouwer CD
    Am J Obstet Gynecol; 2003 Nov; 189(5):1221-7. PubMed ID: 14634544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.
    Scarabin PY; Alhenc-Gelas M; Plu-Bureau G; Taisne P; Agher R; Aiach M
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3071-8. PubMed ID: 9409295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.
    Post MS; Christella M; Thomassen LG; van der Mooren MJ; van Baal WM; Rosing J; Kenemans P; Stehouwer CD
    Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1116-21. PubMed ID: 12730085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
    Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
    Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial.
    Hemelaar M; Kenemans P; Hack CE; Klipping C; van der Mooren MJ
    Menopause; 2008; 15(2):248-55. PubMed ID: 17693902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells.
    Quehenberger P; Kapiotis S; Pärtan C; Schneider B; Wenzel R; Gaiger A; Speiser W
    Ann Hematol; 1993 Jul; 67(1):33-6. PubMed ID: 8392873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Estrogen replacement in postmenopause, blood coagulation and fibrinolysis: comparison of a new kind of transdermal estradiol treatment with oral therapy with conjugated estrogens].
    Winkler UH; Krämer R; Kwee B; Schindler AE
    Zentralbl Gynakol; 1995; 117(10):540-8. PubMed ID: 7491837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration?
    Brosnan JF; Sheppard BL; Norris LA
    Thromb Haemost; 2007 Apr; 97(4):558-65. PubMed ID: 17393018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pulsed estrogen therapy on hemostatic markers in comparison with oral estrogen regimen in postmenopausal women.
    Basurto L; Saucedo R; Zárate A; Martínez C; Gaminio E; Reyes E; Hernandez M
    Gynecol Obstet Invest; 2006; 61(2):61-4. PubMed ID: 16192735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein(a) in postmenopausal women: a randomized, placebo-controlled study.
    Hemelaar M; van der Mooren MJ; Mijatovic V; Bouman AA; Schijf CP; Kroeks MV; Franke HR; Kenemans P
    Menopause; 2003; 10(6):550-8. PubMed ID: 14627865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease.
    Lindoff C; Peterson F; Lecander I; Martinsson G; Astedt B
    Maturitas; 1996 May; 24(1-2):43-50. PubMed ID: 8794433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of transdermal and oral oestrogen replacement therapy on C-reactive protein levels in postmenopausal women: a randomised, placebo-controlled trial.
    Post MS; van der Mooren MJ; Stehouwer CD; van Baal WM; Mijatovic V; Schalkwijk CG; Kenemans P
    Thromb Haemost; 2002 Oct; 88(4):605-10. PubMed ID: 12362231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose oral combination of 17beta-estradiol and norethisterone acetate in postmenopausal women decreases factor VII, fibrinogen, antithrombin and plasminogen activator inhibitor-1.
    Borgfeldt C; Li C; Samsioe G
    Climacteric; 2004 Mar; 7(1):78-85. PubMed ID: 15259286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of transdermal and oral postmenopausal hormone therapy on vascular function: a randomized, placebo-controlled study in healthy postmenopausal women.
    Hemelaar M; van der Mooren MJ; van Baal WM; Schalkwijk CG; Kenemans P; Stehouwer CD
    Menopause; 2005; 12(5):526-35. PubMed ID: 16145306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis.
    Teede HJ; McGrath BP; Smolich JJ; Malan E; Kotsopoulos D; Liang YL; Peverill RE
    Arterioscler Thromb Vasc Biol; 2000 May; 20(5):1404-9. PubMed ID: 10807761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis.
    Zegura B; Keber I; Sebestjen M; Koenig W
    Atherosclerosis; 2003 May; 168(1):123-9. PubMed ID: 12732395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone replacement therapy and hemostasis: effects in Brazilian postmenopausal women.
    Callejon DR; Franceschini SA; Montes MB; Toloi MR
    Maturitas; 2005; 52(3-4):249-55. PubMed ID: 16257613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women.
    Vogelvang TE; Mijatovic V; Kenemans P; Emeis JJ; Heijst JA; van der Mooren MJ
    Am J Obstet Gynecol; 2005 Oct; 193(4):1384-94. PubMed ID: 16202731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized placebo-controlled study of the effect of transdermal vs. oral estradiol with or without gestodene on homocysteine levels.
    Smolders RG; van der Mooren MJ; Teerlink T; Merkus JM; Kroeks MV; Franke HR; Stehouwer CD; Kenemans P
    Fertil Steril; 2003 Feb; 79(2):261-7. PubMed ID: 12568832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.